<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183064</url>
  </required_header>
  <id_info>
    <org_study_id>107.210</org_study_id>
    <nct_id>NCT02183064</nct_id>
  </id_info>
  <brief_title>Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis</brief_title>
  <official_title>A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis of the Hip, Knee, Hand or Spine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to compare the percentage of treatment successes or failures in patients randomized to&#xD;
      meloxicam 7.5 mg vs. usual care prescription NSAIDs. Additionally, health care utilization,&#xD;
      efficacy and safety of patients in a managed healthcare setting with osteoarthritis (OA) of&#xD;
      the hip, knee, hand or spine will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <primary_completion_date type="Actual">November 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of treatment successes and failures in patients randomized to meloxicam 7.5 mg vs.usual care prescription NSAIDs</measure>
    <time_frame>up to 6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment of Disease Activity (Likert)</measure>
    <time_frame>Screening (Day 0), after six month (Day 180)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's overall Assessment of pain over the past week on a visual analogue scale (VAS)</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Assessment of Health Status (VAS)</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Assessment of Satisfaction of Health</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility Index (VAS)</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and Mc Master University Osteoarthritis Index (WOMAC)</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Compliance</measure>
    <time_frame>Day 30, day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability Index</measure>
    <time_frame>Screening (Day 0), after six month (Day 180)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent Discontinuation of Study Medication related to lack of efficacy</measure>
    <time_frame>up to day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and intensity of adverse events</measure>
    <time_frame>from day 30 until day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent Discontinuation of Study Medication related to adverse event</measure>
    <time_frame>from day 30 until day 180</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1309</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Meloxicam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care prescription NSAID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <arm_group_label>Meloxicam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NSAID</intervention_name>
    <arm_group_label>Usual care prescription NSAID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females over the age of 18&#xD;
&#xD;
          -  The patient, if female and of reproductive potential (i.e. neither surgically&#xD;
             sterilized nor post-menopausal), must be practicing adequate contraception (e.g.&#xD;
             intrauterine device, contraceptive pills, Depo-Provera, or implant or double barrier&#xD;
             device) for at least three months prior to and for the duration of their trial&#xD;
             participation and must have a negative pregnancy test at screening. Abstinence is not&#xD;
             considered to be an acceptable method of contraception. (It should be noted that&#xD;
             NSAIDs might interfere with the effectiveness of intrauterine devices)&#xD;
&#xD;
          -  The patient must have a documented diagnosis of at least one of the following:&#xD;
&#xD;
               -  Osteoarthritis of the hip&#xD;
&#xD;
               -  Osteoarthritis of the knee&#xD;
&#xD;
               -  Osteoarthritis of the hand or&#xD;
&#xD;
               -  Osteoarthritis of the spine - Patients must have radiographic confirmation of the&#xD;
                  diagnosis&#xD;
&#xD;
          -  The patient is willing to change or requires a change in current prescription NSAID&#xD;
             therapy or requires initiation of prescription NSAID therapy for treatment of OA of&#xD;
             the hip, knee, hand or spine&#xD;
&#xD;
          -  The patient intends to remain a member of their present Managed Care Organization&#xD;
             (MCO) for the duration of the trial&#xD;
&#xD;
          -  The patient is willing to comply with instructions and to provide written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has a known or suspected hypersensitivity to the trial drugs or their&#xD;
             excipients, analgesics, antipyretics or NSAIDS (prescription or over-the-counter)&#xD;
&#xD;
          -  The patient has received an investigational drug or used an investigational device&#xD;
             within 30 days prior to entering the trial&#xD;
&#xD;
          -  In the opinion of the investigator the patient has any disease or condition that may&#xD;
             result in altered absorption, excess accumulation or impaired metabolism or excretion&#xD;
             of the trial medication&#xD;
&#xD;
          -  The patient has a history of recurrent peptic ulcer or history (within the past 6&#xD;
             months) of gastrointestinal perforation, peptic ulceration documented by endoscopy or&#xD;
             radiography, symptomatic hiatal hernia requiring daily treatment or any history of a&#xD;
             gastrointestinal tract hemorrhage, except simple hemorrhoidal bleeding&#xD;
&#xD;
          -  The patient is currently on coumadin or might be placed on coumadin during the course&#xD;
             of the clinical trial&#xD;
&#xD;
          -  Patients with dementia, i.e. incapable of following directions or complying with the&#xD;
             study protocol&#xD;
&#xD;
          -  Patients with co-existing rheumatological disorders including rheumatoid arthritis&#xD;
&#xD;
          -  The patient has previously participated in this trial&#xD;
&#xD;
          -  Patients with coexisting fibromyalgia or ankylosing spondylitis&#xD;
&#xD;
          -  Patient is pregnant or lactating&#xD;
&#xD;
          -  Patient has severe hepatic failure&#xD;
&#xD;
          -  Patient has non-dialysed renal failure&#xD;
&#xD;
          -  Patient has history of GI bleed within the past 6 months&#xD;
&#xD;
          -  Patient has history of cerebrovascular bleeding or other bleeding disorders&#xD;
&#xD;
          -  Patient is receiving concomitant lithium, heparin or ticlopidine therapy&#xD;
&#xD;
          -  Patient has a history of leukopenia (White Blood Cell count &lt; 3500/mmÂ³)&#xD;
&#xD;
          -  The patient has a history of platelet count below the lower limit of normal or has a&#xD;
             documented abnormal prothrombin time (PT) or partial thromboplastin time (PTT)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.210_U01-3301.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

